342 related articles for article (PubMed ID: 31781306)
41. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
42. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
[TBL] [Abstract][Full Text] [Related]
43. Are breast cancer molecular classes predictive of survival in patients with long follow-up?
Pracella D; Bonin S; Barbazza R; Sapino A; Castellano I; Sulfaro S; Stanta G
Dis Markers; 2013; 35(6):595-605. PubMed ID: 24288429
[TBL] [Abstract][Full Text] [Related]
44. Predicting axillary sentinel node status in patients with primary breast cancer.
Kolarik D; Pecha V; Skovajsova M; Zahumensky J; Trnkova M; Petruzelka L; Halaska M; Sottner O; Otcenasek M; Kolarova H
Neoplasma; 2013; 60(3):334-42. PubMed ID: 23374005
[TBL] [Abstract][Full Text] [Related]
45. LAT1 (SLC7A5) Overexpression in Negative Her2 Group of Breast Cancer: A Potential Therapy Target.
Bodoor K; Almomani R; Alqudah M; Haddad Y; Samouri W
Asian Pac J Cancer Prev; 2020 May; 21(5):1453-1458. PubMed ID: 32458655
[TBL] [Abstract][Full Text] [Related]
46. Tumor characteristics and therapy of elderly patients with breast cancer.
Grumpelt AM; Ignatov A; Tchaikovski SN; Burger E; Costa SD; Eggemann H
J Cancer Res Clin Oncol; 2016 May; 142(5):1109-16. PubMed ID: 26809246
[TBL] [Abstract][Full Text] [Related]
47. Breast Cancer Outcomes After Diagnosis of Hormone-positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era.
Nye L; Rademaker A; Gradishar WJ
Clin Breast Cancer; 2017 Jul; 17(4):e185-e189. PubMed ID: 28185739
[TBL] [Abstract][Full Text] [Related]
48. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
49. [PIK3CA mutation is an independent indicator of malignant phenotype and prognosis in breast cancer].
Li SY; Wang W; Li JM; Wang Z; Wen RY; Chen J; Miao XT
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):605-8. PubMed ID: 22325221
[TBL] [Abstract][Full Text] [Related]
50. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
51. Breast cancer molecular subtypes and associations with clinicopathological characteristics in Iranian women, 2002- 2011.
Kadivar M; Mafi N; Joulaee A; Shamshiri A; Hosseini N
Asian Pac J Cancer Prev; 2012; 13(5):1881-6. PubMed ID: 22901141
[TBL] [Abstract][Full Text] [Related]
52. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
[TBL] [Abstract][Full Text] [Related]
53. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
54. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
55. Patterns of Relative Telomere Length is Associated With hTERT Gene Expression in the Tissue of Patients With Breast Cancer.
Thriveni K; Raju A; Kumar RV; Krishnamurthy S; Chaluvarayaswamy R
Clin Breast Cancer; 2019 Feb; 19(1):27-34. PubMed ID: 30217473
[TBL] [Abstract][Full Text] [Related]
56. Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample.
Zhu S; Wu J; Huang O; He J; Zhu L; Li Y; Chen W; Fei X; Chen X; Shen K
Ann Surg Oncol; 2019 Sep; 26(9):2779-2786. PubMed ID: 31144143
[TBL] [Abstract][Full Text] [Related]
57. A study of high-nuclear-grade breast cancer in Thailand: subclassification and correlation with prognostic factors and immunohistochemical study.
Chaiwun B; Nakrungsee S; Sukhamwang N; Srisukho S
Breast Cancer; 2010; 17(1):35-41. PubMed ID: 19789946
[TBL] [Abstract][Full Text] [Related]
58. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
[TBL] [Abstract][Full Text] [Related]
59. Hepatosteatosis may predict late recurrence of breast cancer: A single-center observational study.
Kus T; Cinkir HY; Aktas G; Abali H
Curr Probl Cancer; 2019 Dec; 43(6):100461. PubMed ID: 30686567
[TBL] [Abstract][Full Text] [Related]
60. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
